Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

Bridel, Claire; Beauverd, Yan; Samii, Kaveh; Lalive d'Epinay, Patrice

doi:10.1212/NXI.0000000000000123

Scientific article

Open access

English

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

ContributorsBridel, Claire

; Beauverd, Yan; Samii, Kaveh; Lalive d'Epinay, Patrice

Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 4, e123

Publication date2015

Abstract

To monitor the hematologic modifications in the peripheral blood of patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Affiliation

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Research group

Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)

Citation (ISO format)

BRIDEL, Claire et al. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 4, p. e123. doi: 10.1212/NXI.0000000000000123

Article (Published version)

Identifiers

PID : unige:84046
DOI : 10.1212/NXI.0000000000000123
PMID : 26140281

ISSN of the journal2332-7812

421views

274downloads

Creation01/27/2016 11:50:00 AM

First validation01/27/2016 11:50:00 AM

Update time03/15/2023 12:23:50 AM

Status update03/15/2023 12:23:50 AM

Last indexation01/16/2024 8:54:33 PM

Archive ouverte UNIGE

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

To monitor the hematologic modifications in the peripheral blood of patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Technical informations